{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:57:48Z","timestamp":1777658268566,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,13]]},"DOI":"10.7759\/cureus.77363","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T12:02:07Z","timestamp":1736769727000},"source":"Crossref","is-referenced-by-count":1,"title":["Paradoxical Inflammatory Bowel Disease Induced by Golimumab in a Patient With Ankylosing Spondylitis: A Case Report and Systematic Review"],"prefix":"10.7759","author":[{"given":"Khalid A","family":"Alnaqbi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amna","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Alaswad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro S","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al.. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023, 82:19-34. 10.1136\/ard-2022-223296","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01008-6","article-title":"Strategies for targeting cytokines in inflammatory bowel disease","volume":"24","author":"Neurath MF","year":"2024","unstructured":"Neurath MF. Strategies for targeting cytokines in inflammatory bowel disease. Nat Rev Immunol. 2024, 24:559-76. 10.1038\/s41577-024-01008-6","journal-title":"Nat Rev Immunol"},{"key":"ref3","article-title":"Golimumab","author":"Padda IS","year":"2024","unstructured":"Padda IS, Bhatt R, Parmar M. Golimumab. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: a double-edged sword?","volume":"9","author":"Ramos-Casals M","year":"2010","unstructured":"Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev. 2010, 9:188-93. 10.1016\/j.autrev.2009.10.003","journal-title":"Autoimmun Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot \u00c9","year":"2016","unstructured":"Toussirot \u00c9, Aubin F. Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016, 2:e000239. 10.1136\/rmdopen-2015-000239","journal-title":"RMD Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50726","article-title":"Paradoxical psoriasis and worsening spondylitis due to secukinumab in a patient with ankylosing spondylitis: a case report and literature review","volume":"15","author":"Alnaqbi KA","year":"2023","unstructured":"Alnaqbi KA, Al Zeyoudi J, Fazal F, Alhaj OM, Jassim I, Albreiki FA. Paradoxical psoriasis and worsening spondylitis due to secukinumab in a patient with ankylosing spondylitis: a case report and literature review. Cureus. 2023, 15:e50726. 10.7759\/cureus.50726","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer L","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, et al.. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015, 350:g7647. 10.1136\/bmj.g7647","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad MH","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018, 23:60-3. 10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid Based Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/art.30546","article-title":"Induction of inflammatory bowel disease flares by golimumab: report of three patients with enteropathic spondylarthritis or ankylosing spondylitis and comorbid colitis","volume":"63","author":"Fiehn C","year":"2011","unstructured":"Fiehn C, Vay S. Induction of inflammatory bowel disease flares by golimumab: report of three patients with enteropathic spondylarthritis or ankylosing spondylitis and comorbid colitis. Arthritis Rheum. 2011, 63:3640-1. 10.1002\/art.30546","journal-title":"Arthritis Rheum"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e31825e6089","article-title":"Golimumab may induce exacerbation of inflammatory bowel disease when it is used for the treatment of ankylosing spondylitis: a case report with a review of literature","volume":"21","author":"Bawany MZ","year":"2014","unstructured":"Bawany MZ, Rafiq E, Thotakura R, Lay R, Silverman AL, Nawras A. Golimumab may induce exacerbation of inflammatory bowel disease when it is used for the treatment of ankylosing spondylitis: a case report with a review of literature. Am J Ther. 2014, 21:e26-7. 10.1097\/MJT.0b013e31825e6089","journal-title":"Am J Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2022.0067","article-title":"Paradoxical reactions to biologicals in chronic inflammatory systemic diseases","volume":"119","author":"Kremenevski I","year":"2022","unstructured":"Kremenevski I, Sander O, Sticherling M, Raithel M, LastName FM. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases. Dtsch Arztebl Int. 2022, 119:88-95. 10.3238\/arztebl.m2022.0067","journal-title":"Dtsch Arztebl Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-012-0244-x","article-title":"Is indeterminate colitis determinable?","volume":"14","author":"Tremaine WJ","year":"2012","unstructured":"Tremaine WJ. Is indeterminate colitis determinable?. Curr Gastroenterol Rep. 2012, 14:162-5. 10.1007\/s11894-012-0244-x","journal-title":"Curr Gastroenterol Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03171-5","article-title":"Clinical features of inflammatory bowel disease unclassified: a case-control study","volume":"24","author":"Shao Y","year":"2024","unstructured":"Shao Y, Zhao Y, Lv H, et al.. Clinical features of inflammatory bowel disease unclassified: a case-control study. BMC Gastroenterol. 2024, 24:105. 10.1186\/s12876-024-03171-5","journal-title":"BMC Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-011-0198-2","article-title":"Mucosal inflammation in spondylarthritides: past, present, and future","volume":"13","author":"Van Praet L","year":"2011","unstructured":"Van Praet L, Van den Bosch F, Mielants H, Elewaut D. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep. 2011, 13:409-15. 10.1007\/s11926-011-0198-2","journal-title":"Curr Rheumatol Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K","article-title":"Approaches for identifying and defining environmentally associated rheumatic disorders","volume":"43","author":"Miller FW","year":"2000","unstructured":"Miller FW, Hess EV, Clauw DJ, et al.. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum. 2000, 43:243-9. 10.1002\/1529-0131(200002)43:2&lt;243::AID-ANR2&gt;3.0.CO;2-K","journal-title":"Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-022-01172-0","article-title":"Extrapulmonary tuberculos\u0131s: an old but resurgent problem","volume":"13","author":"Baykan AH","year":"2022","unstructured":"Baykan AH, Sayiner HS, Aydin E, Koc M, Inan I, Erturk SM. Extrapulmonary tuberculos\u0131s: an old but resurgent problem. Insights Imaging. 2022, 13:39. 10.1186\/s13244-022-01172-0","journal-title":"Insights Imaging"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.154799","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study","volume":"71","author":"Braun J","year":"2012","unstructured":"Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, Hsu B. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012, 71:661-7. 10.1136\/ard.2011.154799","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205862","article-title":"Golimumab administered subcutaneously every 4\u2005weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study","volume":"74","author":"Deodhar A","year":"2015","unstructured":"Deodhar A, Braun J, Inman RD, et al.. Golimumab administered subcutaneously every 4\u2005weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis. 2015, 74:757-61. 10.1136\/annrheumdis-2014-205862","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone EC","year":"2009","unstructured":"Keystone EC, Genovese MC, Klareskog L, et al.. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009, 68:789-96. 10.1136\/ard.2008.099010","journal-title":"Ann Rheum Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203229","article-title":"Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study","volume":"73","author":"Combe B","year":"2014","unstructured":"Combe B, Dasgupta B, Louw I, et al.. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis. 2014, 73:1477-86. 10.1136\/annrheumdis-2013-203229","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy079","article-title":"Long-term benefit of golimumab for patients with moderately to severely active ulcerative colitis: results from the PURSUIT-maintenance extension","volume":"12","author":"Reinisch W","year":"2018","unstructured":"Reinisch W, Gibson PR, Sandborn WJ, et al.. Long-term benefit of golimumab for patients with moderately to severely active ulcerative colitis: results from the PURSUIT-maintenance extension. J Crohns Colitis. 2018, 12:1053-66. 10.1093\/ecco-jcc\/jjy079","journal-title":"J Crohns Colitis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker359","article-title":"Validation of the Dudley inflammatory bowel symptom questionnaire for the assessment of bowel symptoms in axial SpA: prevalence of clinically relevant bowel symptoms and association with disease activity","volume":"51","author":"Stebbings S","year":"2012","unstructured":"Stebbings S, Jenks K, Treharne GJ, Garc\u00eda JA, Schultz M, Highton J, Dudley-Brown S. Validation of the Dudley inflammatory bowel symptom questionnaire for the assessment of bowel symptoms in axial SpA: prevalence of clinically relevant bowel symptoms and association with disease activity. Rheumatology (Oxford). 2012, 51:858-65. 10.1093\/rheumatology\/ker359","journal-title":"Rheumatology (Oxford)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200012020-00015","article-title":"Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats","volume":"12","author":"Karmeli F","year":"2000","unstructured":"Karmeli F, Cohen P, Rachmilewitz D. Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur J Gastroenterol Hepatol. 2000, 12:223-31. 10.1097\/00042737-200012020-00015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref24","article-title":"Coxib\u2019s safety in patients with inflammatory bowel diseases: a meta-analysis","volume":"18","author":"Ribaldone DG","year":"2015","unstructured":"Ribaldone DG, Fagoonee S, Astegiano M, et al.. Coxib\u2019s safety in patients with inflammatory bowel diseases: a meta-analysis. Pain Physician. 2015, 18:599-607.","journal-title":"Pain Physician"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e328020045a","article-title":"Nonsteroidal antiinflammatory drugs and the small intestine","volume":"23","author":"Fortun PJ","year":"2007","unstructured":"Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol. 2007, 23:134-41. 10.1097\/MOG.0b013e328020045a","journal-title":"Curr Opin Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/life13081779","article-title":"Inflammatory bowel disease as a paradoxical reaction to anti-TNF-\u03b1 treatment-a review","volume":"13","author":"Mihai IR","year":"2023","unstructured":"Mihai IR, Burlui AM, Rezus II, et al.. Inflammatory bowel disease as a paradoxical reaction to anti-TNF-\u03b1 treatment-a review. Life (Basel). 2023, 13:1779. 10.3390\/life13081779","journal-title":"Life (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.06.004","article-title":"Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action","volume":"39","author":"Haraoui B","year":"2009","unstructured":"Haraoui B, Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum. 2009, 39:176-81. 10.1016\/j.semarthrit.2008.06.004","journal-title":"Semin Arthritis Rheum"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2011.10.001","article-title":"Development of inflammatory bowel disease during anti-TNF-\u03b1 therapy for inflammatory rheumatic disease: a nationwide series","volume":"79","author":"Toussirot \u00c9","year":"2012","unstructured":"Toussirot \u00c9, Houvenagel \u00c9, Go\u00ebb V, et al.. Development of inflammatory bowel disease during anti-TNF-\u03b1 therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine. 2012, 79:457-63. 10.1016\/j.jbspin.2011.10.001","journal-title":"Joint Bone Spine"},{"key":"ref29","article-title":"Development of Crohn's disease in a patient taking etanercept","volume":"32","author":"Oh J","year":"2005","unstructured":"Oh J, Arkfeld DG, Horwitz DA. Development of Crohn's disease in a patient taking etanercept. J Rheumatol. 2005, 32:752-3.","journal-title":"J Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08009.x","article-title":"Development of Crohn disease in a patient on etanercept for psoriasis","volume":"157","author":"Ahmad K","year":"2007","unstructured":"Ahmad K, Rogers S. Development of Crohn disease in a patient on etanercept for psoriasis. Br J Dermatol. 2007, 157:396. 10.1111\/j.1365-2133.2007.08009.x","journal-title":"Br J Dermatol"},{"key":"ref31","article-title":"New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept","volume":"35","author":"Song IH","year":"2008","unstructured":"Song IH, Appel H, Haibel H, Loddenkemper C, Braun J, Sieper J, Rudwaleit M. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol. 2008, 35:532-6.","journal-title":"J Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1080\/00365520601106228","article-title":"First appearance of Crohn's disease following infliximab treatment for spondylarthropathy","volume":"42","author":"Tsochatzis E","year":"2007","unstructured":"Tsochatzis E, Vassilopoulos D, Manesis EK, Papatheodoridis G, Bousiotou A, Hadziyannis E, Archimandritis AJ. First appearance of Crohn's disease following infliximab treatment for spondylarthropathy. Scand J Gastroenterol. 2007, 42:784-5. 10.1080\/00365520601106228","journal-title":"Scand J Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1318.2008.01490.x","article-title":"Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept)","volume":"10","author":"Yazisiz V","year":"2008","unstructured":"Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzio\u011flu E. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis. 2008, 10:953-4. 10.1111\/j.1463-1318.2008.01490.x","journal-title":"Colorectal Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2174\/1874312900802010053","article-title":"The changing face of spondyloarthropathies under TNF \u03b1 blockade","volume":"2","author":"Elkayam O","year":"2008","unstructured":"Elkayam O, Litinsky I, Levartovsky D, Caspi D. The changing face of spondyloarthropathies under TNF \u03b1 blockade. Open Rheumatol J. 2008, 2:53-7. 10.2174\/1874312900802010053","journal-title":"Open Rheumatol J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200408000-00016","article-title":"Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis","volume":"39","author":"Ruemmele FM","year":"2004","unstructured":"Ruemmele FM, Prieur AM, Talbotec C, Goulet O, Schmitz J. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr. 2004, 39:203-6. 10.1097\/00005176-200408000-00016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-0991-7","article-title":"Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature","volume":"30","author":"Wiegering V","year":"2010","unstructured":"Wiegering V, Morbach H, Dick A, Girschick HJ. Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int. 2010, 30:801-4. 10.1007\/s00296-009-0991-7","journal-title":"Rheumatol Int"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq136","article-title":"Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study","volume":"49","author":"Dallocchio A","year":"2010","unstructured":"Dallocchio A, Canioni D, Ruemmele F, et al.. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford). 2010, 49:1694-8. 10.1093\/rheumatology\/keq136","journal-title":"Rheumatology (Oxford)"},{"key":"ref38","article-title":"Emergence of Crohn's disease in juvenile idiopathic arthritis during treatment with etanercept: a causal link or a mere coincidence?","volume":"19","author":"Oikonomou KA","year":"2010","unstructured":"Oikonomou KA, Kapsoritakis AN, Tsiopoulos FD, Tsikouras AN, Potamianos S. Emergence of Crohn's disease in juvenile idiopathic arthritis during treatment with etanercept: a causal link or a mere coincidence?. J Gastrointestin Liver Dis. 2010, 19:342.","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2010.499878","article-title":"Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab","volume":"40","author":"Tarkiainen M","year":"2011","unstructured":"Tarkiainen M, Tynj\u00e4l\u00e4 P, V\u00e4h\u00e4salo P, Lahdenne P. Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab. Scand J Rheumatol. 2011, 40:150-2. 10.3109\/03009742.2010.499878","journal-title":"Scand J Rheumatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab678","article-title":"Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use","volume":"61","author":"van Straalen JW","year":"2022","unstructured":"van Straalen JW, Krol RM, Giancane G, et al.. Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use. Rheumatology (Oxford). 2022, 61:2104-12. 10.1093\/rheumatology\/keab678","journal-title":"Rheumatology (Oxford)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/art.22669","article-title":"Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents","volume":"57","author":"Braun J","year":"2007","unstructured":"Braun J, Baraliakos X, Listing J, et al.. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007, 57:639-47. 10.1002\/art.22669","journal-title":"Arthritis Rheum"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.09.003","article-title":"Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-\u03b1 inhibitor","volume":"32","author":"Boyce EG","year":"2010","unstructured":"Boyce EG, Halilovic J, Stan-Ugbene O. Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-\u03b1 inhibitor. Clin Ther. 2010, 32:1681-703. 10.1016\/j.clinthera.2010.09.003","journal-title":"Clin Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2018.04.003","article-title":"Paradoxical reactions to biologic therapy in psoriasis: a review of the literature","volume":"109","author":"Munera-Campos M","year":"2018","unstructured":"Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical reactions to biologic therapy in psoriasis: a review of the literature. Actas Dermosifiliogr (Engl Ed). 2018, 109:791-800. 10.1016\/j.ad.2018.04.003","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnma.2018.10.003","article-title":"Do anti-TNF agents increase the risk of inflammatory bowel disease evolution in patients with ankylosing spondylitis? Real life data","volume":"111","author":"\u00dcsk\u00fcdar Cansu D","year":"2019","unstructured":"\u00dcsk\u00fcdar Cansu D, \u00dcsk\u00fcdar Teke H, Temel T, Ert\u00fcrk A, Kahraman O, Korkmaz C. Do anti-TNF agents increase the risk of inflammatory bowel disease evolution in patients with ankylosing spondylitis? Real life data. J Natl Med Assoc. 2019, 111:262-9. 10.1016\/j.jnma.2018.10.003","journal-title":"J Natl Med Assoc"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.211034","article-title":"Inflammatory bowel disease risk in patients with axial spondyloarthritis treated with biologic agents determined using the BSRBR-AS and a metaanalysis","volume":"50","author":"Macfarlane GJ","year":"2023","unstructured":"Macfarlane GJ, Biallas R, Dean LE, Jones GT, Goodson NJ, Rotariu O. Inflammatory bowel disease risk in patients with axial spondyloarthritis treated with biologic agents determined using the BSRBR-AS and a metaanalysis. J Rheumatol. 2023, 50:175-84. 10.3899\/jrheum.211034","journal-title":"J Rheumatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: recent advances","volume":"15","author":"Honap S","year":"2024","unstructured":"Honap S, Agorogianni A, Colwill MJ, et al.. JAK inhibitors for inflammatory bowel disease: recent advances. Frontline Gastroenterol. 2024, 15:59-69. 10.1136\/flgastro-2023-102400","journal-title":"Frontline Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/333369-paradoxical-inflammatory-bowel-disease-induced-by-golimumab-in-a-patient-with-ankylosing-spondylitis-a-case-report-and-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T12:02:10Z","timestamp":1736769730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/333369-paradoxical-inflammatory-bowel-disease-induced-by-golimumab-in-a-patient-with-ankylosing-spondylitis-a-case-report-and-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.77363","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,13]]}}}